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Abstract
Background. Seasonal influenza can cause a significant public health burden. Vaccina-
tion is proposed as the most effective measure to prevent influenza and related undesired 
outcomes. 
Objective. To estimate the efficiency of influenza vaccination. 
Methods. A literature review of economic evaluations of influenza vaccinations, pub-
lished over the last 5 years, was performed using MEDLINE (through PubMed), Web 
of Science and Scopus.
Results. 935 papers were identified and 30 were selected, including studies performed 
in different population subgroups: general population, children, adults, elderly, pregnant 
women and high risk patients. Twenty-one studies were performed in Europe and in US. 
The majority of the studies were carried out on elderly patients and children. All except 
one were cost-effectiveness analyses and reported influenza vaccination as a cost-saving 
or cost-effective intervention. 
Conclusions. Vaccination strategies are economically favourable in a range of countries 
and sub-groups of patients. 
INTRODUCTION
Seasonal influenza is an acute viral infection that 
circulates worldwide and spreads easily from person to 
person. It can affect any age group and cause annual 
epidemics, representing a serious public health and 
economic problem of society, due to increased medical 
resource utilisation and loss of production [1]. 
Vaccination is proposed as the main effective strategy 
for preventing influenza and related complications. An-
nual influenza immunization is recommended in elderly 
subjects, children with ≥ 6 months of age or older, preg-
nant women and individuals with chronic conditions 
[2]; however, these recommendations are different by 
country [3].
Current available influenza vaccines licensed for use 
are Trivalent Inactivated Influenza Vaccine (TIV, IIV3), 
Quadrivalent Inactivated Influenza Vaccine (QIV, IIV4), 
Trivalent Live Attenuated Influenza Vaccines (LAIV3), 
Quadrivalent Live Attenuated Influenza Vaccines 
(LAIV4). Live Attenuated Influenza Vaccines (LAIV) 
are administered intranasally, while Inactivated Vaccines 
(IIV) are administered by intramuscular injection [4].
Despite the number of countries recognizing the im-
portance of vaccines has grown in recent years, it is not 
clear whether the benefits of newer vaccines justify their 
added costs [5].
An increasing number of health-care systems, both 
public and private, are adopting results from economic 
evaluations, as cost-effectiveness analysis (CEA), to 
better understand the clinical and economic impact of 
health technologies, including vaccines, to support de-
cisions on allocation of healthcare resources. The aim 
of this review is to estimate the efficiency of influenza 
vaccination.
METHODS
To collect and critically review the health economics 
evidence on influenza vaccination, a systematic litera-
ture review was performed. Considering as a starting 
point the review published by Peasah and colleagues 
in 2013 [6], and in order to focus on the most recent 
practice, original studies and analyses published over 
the last 5 years (from January 2012 until January 2017) 
were included [6].
The bibliographic search was performed in PubMed, 
Web of Science and Scopus, using “cost effectiveness” 
OR “cost utility” OR “cost benefit” OR “cost conse-
quence” AND “influenza vaccination” as keywords 
research terms. To maximise retrieval of all pertinent 
papers, we applied medical subject headings (MeSH 
terms), or keyword searches when appropriate.
Papers were examined by two members of the team 
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(AL, SR) in a three-steps process. First, the abstract 
was considered; second, potentially relevant articles 
were reviewed in full text; third, articles that met the 
inclusion criteria were analysed. Disagreement between 
the two reviewers was resolved by consensus of a third 
party (PAC). 
Original articles that estimated cost-effectiveness, 
cost-utility or cost-benefit of influenza vaccination, for 
the entire population or specific subgroups (e.g. chil-
dren, elderly), were included. Furthermore, the other 
inclusion criteria used to select the articles were: arti-
cles that summarize findings in English; articles not re-
lated to pandemic influenza; original studies and analy-
ses published between January 2012 and January 2017. 
After scanning all titles and abstracts, full text for all po-
tentially relevant studies were retrieved. Papers focused 
only on cost, without including treatment effectiveness 
(e.g. cost of illness studies) were excluded. Further, 
studies that evaluated the cost-effectiveness of com-
munication campaign on influenza vaccination were 
excluded. Data from eligible studies were extracted and 
a spreadsheet was used for data entry. The extracted 
data were aim, design, perspective, subjects’ character-
istics, description of comparators, data sources, results 
including costs, outcome, authors’ conclusions and In-
cremental Cost-Effectiveness Ratios (ICERs), defined 
as the ratio between the net total costs and the net 
effects. The influenza vaccination strategies assessed 
in the included studies were classified based on their 
cost-effectiveness ratios (e.g. cost per influenza-related 
deaths averted, cost-benefit ratios, cost/influenza cases 
averted) and on the cost-effectiveness threshold that 
each study considered. Those influenza vaccination 
strategies reported as less costly and more effective 
than the comparators were classified as cost-saving.
RESULTS 
The literature search found 253 references in 
PubMed, 462 in Scopus and 220 in Web of Knowledge; 
however, after removal of duplicates (n = 11 studies), all 
abstract were screened, and 888 studies were excluded 
because they did not meet the inclusion criteria. Thirty-
six articles were retrieved for full review, and six of them 
were excluded for different reasons, as reported in Fig-
ure 1. Consequently, 30 papers were included in our sys-
tematic review: 29 studies were CEA and 1 study was a 
cost-benefit analysis (CBA) [7]. Details of the studies 
are presented in the Supplementary Material, Table 1 
available online.
Twelve out of 30 studies were performed in Europe 
[8-19], 9 in USA [5, 7, 20-26], 3 in Canada [18, 27, 
28], 3 in China [29-31], 1 in Turkey [32], 1 in Thailand 
[33], 1 in Australia [34] and 1 in Israel [35].
The payer-only perspective was adopted in 11 studies 
[8-10, 13, 17-19, 24, 31, 34, 35], while the societal-only 
perspective was adopted in 7 studies [5, 20, 22, 26, 28, 
935 Records identied with
Keywords (inuenza, u, vaccine, cost-benet, cost 
eectiveness, cost utility, cost consequence) and  
Mesh Term (cost benet analysis) 
- 253 PubMed
- 462  Scopus
- 220 Web of Knowledge
11 Records after duplicates
removed (from Refwork)
888 Abstract screened and removed
36 Full text assessed for eligibility 
6 Articles excluded:
- 4 Using an inappropriate methods of analysis
- 1 Concerning pneumococcal vaccine
- 1 Concerning hypotethical vaccine (immunity 5-10 years)
30 Articles included
Figure 1
Flow-chart.
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29, 33] and both perspectives were used in 12 studies 
[7, 11, 12, 14-16, 21, 23, 25, 27, 30, 32].
Damm et al. was the only study that performed the 
analysis using a narrow and a broad third-party payer 
perspective: the former perspective included reim-
bursed direct health care costs only, while the latter 
accounted for all reimbursed direct costs and specific 
transfer payments [12]. 
All CEA papers reported the results in terms of IC-
ER’s, presented as cost per Quality Adjusted Life Year 
(QALY) or LY (Life Year) gained, except 3 analyses that 
reported ICER expressed in cost per Disability Adjust-
ed Life Year (DALY) [33], cost per cases of influenza 
averted [28] and cost per life saved [24]. 
Population
Within the 30 studies, 7 assessed the vaccine program 
in the whole population [8, 14, 16, 18, 22, 27, 30], 7 
among children (0-18 years) [12, 17, 19, 25, 26, 28, 33], 
11 among elderly [5, 9-11, 13, 21, 23, 24, 29, 31, 34], 
3 among pregnant women [7, 8, 20], 1 among adult 
healthcare workers [8] and 5 among high risk popula-
tions [9, 10, 15, 32, 35] (Table 1). Generally, subjects 
were considered at high risk if they have a higher prob-
ability to be infected by influenza virus than the general 
population, or if they have a higher risk of developing 
influenza-related complications. Within the high risk 
subpopulations included in the studies, we found sub-
jects affected by chronic respiratory disease; chronic 
heart disease; chronic renal disease; chronic liver dis-
ease; chronic neurological conditions; diabetes melli-
tus; or immunosuppressed [9, 10, 15, 32, 35]. Further, 
Garcia et al. [11] assumed a different risk classification, 
including patients with different clinical risk in only one 
group and patients aged 65 or older, in a second group. 
The first group included the population who was at risk 
Table 1
Vaccination strategies compared in the selected studies by Region and patients’ group
All population Children Adult Elderly Pregnant High-Risk
Europe (12) No vaccination/
Increasing TIV 
uptake [8]
No vaccination/
Current situation/
Increasing TIV 
uptake/Increasing 
LAIV uptake [17]
No 
vaccination/
Increasing TIV 
uptakea [8]
TIV/QIV [9, 11] No vaccination/
Increasing TIV 
uptake [8] 
TIV/QIV [9, 15] 
TIV/QIV [14, 18] No vaccination/ 
Vaccination 
program 
extension [19] 
No vaccination/
Alternative influenza 
vaccination policies 
[10]
No vaccination/
Alternative 
influenza 
vaccination policies 
[10] 
No vaccination/
TIV/QIV/ LAIV4 
% [16]
TIV/TIV+LAIV [12] Current situation/New 
situation (vaccination 
coverage rate) [13] 
USA (9) TIV/QIV [22] LAIV/IIV [25, 26] No Vaccination/TIV/
QIV/TIV HD [21] 
No vaccination/
Vaccination 
[7, 20] 
TIV SD/TIV HD [23]
No vaccination/TIV/
QIV/TIV HD [5]
No vaccination/TIV 
(ED) [24] 
Canada (3) TIV/QIV [18, 27]b Vaccination/No 
vaccination [28]
China (3) TIV /QIV [30] ID vaccine/IM vaccine 
[31] 
TIV/QIV [29]
Turkey (1) Current situation/
Projected situation 
(vaccination 
coverage rate) [32] 
Israel (1) No vaccination/
Vaccination [35] 
Thailand (1) No vaccination/
LAIV/TIV [33] 
Australia (1) No vaccination/
Vaccination [34]
No of studies 
(31)
7 7 1 11 3 5
TIV: Trivalent Inactivated Influenza Vaccine, QIV: Quadrivalent Inactivated Influenza Vaccine, LAIV: Live Attenuated Influenza Vaccine, LAIV4: Quadrivalent Live 
Attenuated Vaccine, IIV: Inactivated Vaccine, HD: High-dose, SD: Standard-dose, IM: Intra-Muscular, ID: Intra-Dermal, ED: Emergency Department.aAnalysis was 
performed on healthcare workers. bThommes et al. performed the analysis in Canada and UK.
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of serious complications from influenza due to other 
conditions and chronic diseases, such as chronic lung 
disease, metabolic disease, morbid obesity, haemoglo-
bin disorders and anaemia, asplenia, severe neuromus-
cular diseases, cochlear implanted, cognitive dysfunc-
tion, people living in institutions, pregnant women and 
children from 6 months to 18 years, receiving long-term 
treatment with acetylsalicylic acid [11]. 
Vaccination strategies
All included studies considered vaccines already on 
the market (but not necessarily in the country where 
the analysis was performed). TIV, QIV, LAIV were in-
cluded in most of them [9, 11, 12, 14-19, 22, 25, 26, 
30, 33]; different vaccination strategies (consisting in 
extending or modifying the vaccination program) were 
also evaluated [8, 10, 13, 19, 32] (Table 1). Influenza 
vaccination was compared with no vaccination in 14 of 
the selected studies [5, 7, 8, 10, 16, 17, 19-21, 24, 28, 
33-35]; while in the other studies different vaccination 
doses (e.g. high-dose (HD) vs standard-dose (SD)) [5, 
21, 23], and/or different types of vaccine (e.g. IIV vs 
LAIV) [25, 26] were compared. Finally, Leung et al. 
compared Intra-Muscular vaccine (IM) vs Intra-Dermal 
(ID) vaccine to the ones who refused the previously of-
fered IM vaccine [31] (Table 1).
Costs 
Following the perspective of the analysis, 13 studies 
investigated only direct cost (all costs directly related to 
the disease, e.g. hospitalizations, visits, pharmaceutical 
therapy) [5, 8-10, 13, 17-19, 24, 26, 31, 34, 35], while 
the other 17 [7, 11, 12, 14-16, 20-23, 25, 27-30, 32, 33] 
included both direct and indirect costs (costs for pro-
duction loss and work absences from the employees’, 
patients’ and caregivers’ perspectives).
In the general population, vaccination was found to 
be more costly than no vaccination. The cost of influ-
enza vaccination with TIV and QIV in the general popu-
lation was found to be similar [14, 18]. However, the 
incremental costs obtained with TIV or QIV was influ-
enced by the analysis perspective (see Supplementary 
Material, Table 2 available online). 
In children, the costs for vaccinated patients were 
usually higher than for unvaccinated [19, 33]. For ex-
ample, in Canada, costs per patient varied widely from 
$32.66 in patients without influenza immunization pro-
grams to $69.07, in patients with immunization [28]. 
Only Pitman et al. in England and Wales estimated that 
the direct costs of no vaccination program were higher 
than the costs of influenza vaccination program, in chil-
dren aged 2-18 years [17] (see Supplementary Material, 
Table 2 available online). 
In elderly patients, the cost associated with vacci-
nation and no vaccination scenarios were comparable 
among studies [5, 13, 24]. However, the results from 
the model of Baguelin et al. [10] showed that in Eng-
land and Wales the vaccination program (consisting in 
the extensions to the elderly and high risk patients) was 
four times more expensive than no vaccination in el-
derly and high risk group (see Supplementary Material, 
Table 2 available online). The majority of the costs of 
the vaccination program were associated with the cost 
of vaccine. However, the incremental cost of the vacci-
nation program was partially counterbalanced by costs 
averted from additional cases of influenza and prevent-
ed hospitalizations.
The studies conducted on pregnant women suggested 
that influenza vaccination can be beneficial in terms of 
costs for society and payers [7, 20], compared with no 
vaccination.
Programs of vaccination against seasonal influenza 
for high risk subgroups were generally more costly than 
no vaccination, except in patients with a positive his-
tory for pneumonia, probably because they were more 
susceptible to become infected and to be hospitalized 
in the subsequent season than the general population 
[35]. QIV was found to be generally more costly than 
TIV [9, 15] ( see Supplementary Material, Table 2 avail-
able online).
Effectiveness
Vaccination programs were more effective than no-
vaccination in all studies, preventing a substantial num-
ber of hospitalizations and deaths and obtaining lower 
total QALYs lost and LYs lost [5, 8, 10, 16, 17, 20-22, 
24, 28, 33, 34].
Different types of vaccinations reported different effi-
cacy within the populations. Several analyses have been 
conducted to compare LAIV vs TIV and various inac-
tivated forms of vaccines. LAIV was more effective in 
preventing illness than IIV in children [25, 26]. Further-
more, LAIV efficacy in children was consistently found 
to be higher than TIV [17]. In Europe, the introduc-
tion of a universal childhood vaccination program using 
LAIV would result in fewer QALYs lost compared with 
TIV (273 483 vs 449 443) [12] (see Supplementary Ma-
terial, Table 3 available online). In an assessment per-
formed on children, Meeyai et al. [33] used the number 
of averted DALYs by specific vaccination policies as 
measure of the overall disease burden, reporting vacci-
nation of children with TIV as more effective than LAIV 
(see Supplementary Material, Table 3 available online). 
In elderly patients high-dose TIV has the potential to 
be favoured over other vaccines (TIV SD, QIV) [5, 21, 
23]. QIV seemed to be effective as TIV, however several 
analyses indicated that QIV would deliver substantial 
health benefits in terms of reduced number of symp-
tomatic influenza cases and deaths and consequent 
gains in QALYs and LYs [24, 29] (see Supplementary 
Material, Table 3 available online).
In adults at risk, QIV would be expected to improve 
health outcomes (QALYs and LYs) and to reduce in-
fluenza related events, compared with TIV [9]. In UK, 
QIV was estimated to avoid 1.4 million influenza cas-
es, nearly 42 thousand hospitalizations and almost 20 
thousand deaths and to gain more than 50 thousands 
QALYs and LYs, compared with TIV [15], when used 
in the at risk population (see Supplementary Material, 
Table 3 available online). 
Cost-effectiveness
The most common cost-effectiveness measures re-
ported in the included studies were cost per QALY and 
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LY (Table 2). The Cost-Effectiveness results of influenza 
vaccination programs compared with no vaccination 
are reported in Figure 2a and 2b, stratified by the per-
spectives adopted in the analysis. From the payer’s per-
spective (Figure 2a), two studies reported vaccination 
as cost-saving strategy (1 in children and 1 in patients 
at high risk); eight studies had an ICER below €20,000 
(2 in general population, 1 in children, 3 in elderly, 1 in 
pregnant women and 1 in patients at risk). Two stud-
ies focussing, respectively, on adult patients and elderly 
reported an ICER between €20,000 and €50,000. Only 
one study in pregnant women reported an expected 
Table 2
Incremental Cost-Effectiveness Ratios (ICERs) reported in the selected studies by Region and patients’ group
All population Children Adult Elderly Pregnant High-Risk
Belgium (1) ICER for increasing 
TIV: 14,378-24,768 €/
QALY [8]
ICER for 
increasing TIV: 
24,096 €/QALY 
[8]
ICER for 
increasing TIV: 
6,616 €/QALY 
[8]
UK/Wales (5) ICERs for QIV: 7,656 
£/QALY and 10,722 
£/LY [18]
Current policy 
with or without 
TIV and LAIV vs 
No vaccination 
was cost saving 
[17]
ICERs for QIV: 5,299 
£/QALY and 5,144 £/
LY [9] 
ICERs for QIV: 
5,299 £/QALY 
and 5,144 £/
LY [9]
ICER for 
vaccination: 
3,117-16,152 £/
QALY [19]
ICER for alternative 
influenza vaccination 
policies was 7,475 £/
QALY [10]
ICER for 
alternative 
influenza 
vaccination 
policies was 
7,475 £/QALY 
[10]
Spain (1) ICER for QIV: 8,748-
11,188 €/QALY [11]
Germany (3) QIV was cost-saving 
from SP and cost 
effective from PP 
(ICER 14,461 €/QALY) 
[14]
TIV + LAIV was 
cost-saving from 
SP and cost 
effective from PP 
(ICER 1,228-2,265 
€/QALY) [12]
ICERs for QIV: 
13,497-14,645 
£/QALY and 
13,067-14,178 £/
LY from SP and 
PP [15]
Finland (1) QIV ± LAIV and 
TIV + LAIV vs No 
vaccination were 
cost- saving from SP. 
QIV/TIV ± LAIV were 
cost-effective from 
PP [16]
Poland (1) ICER for new situation: 
26,118 PLN/QALY [13]
USA (9) ICER for QIV was 
90,301 $/QALY [22]
LAIV was cost-
saving [26]
HD TIV, TIV and QIV vs 
No vaccination were 
cost-effective (ICERs 
8,833 $/QALY, 11,331 
$/QALY and 15,001 $/
QALY) [21]
Vaccination 
was cost-
saving [20]
LAIV was cost-
effective [25]
TIV HD was cost-saving 
[23]
Vaccination 
was cost-
beneficial from 
SP. Vaccination 
would not 
generate net 
savings from 
PP [7]
ICER for TIV vs No 
vaccination: 3,693 $/
QALY [5]
ICER for vaccination: 
13,084-34,610 $ per life 
saved [24]
Continues
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negative net societal benefit when vaccinated mothers 
were compared with unvaccinated mothers. From the 
societal perspective, one study in the general population 
found that vaccination was cost-saving compared to no 
vaccination and one study in pregnant women, showed 
that vaccination generated net cost saving. Five studies 
reported an ICER between €20,000 and €50,000: such 
studies were carried out in children (n = 2), in elderly (n 
= 2) and in pregnant women (n = 1) (Figure 2b).
The definition of cost-effectiveness was based on dif-
ferent cost-effectiveness threshold values, according to 
different studies jurisdictions between Countries. The 
threshold used in studies performed in Europe ranged 
from €20,000 to €50,000 per QALY or LY gained, 
£20,000-30,000 per QALY or LY gained or three times 
GDP per capita of the country. Studies performed in 
US, in China, in Turkey and in Canada adopted the 
threshold values of $50,000, $100,000 or three times 
GDP per capita to define the influenza vaccination as 
cost-effective. 
More than half of the selected studies did not include 
no vaccination as a comparator: on the contrary, they 
focused on CEA of different vaccination strategies, 
among different populations, countries and perspec-
tives. Within these studies, TIV was the most common-
ly evaluated vaccination strategy, and it was generally 
compared to LAIV and QIV (Table 2). Three studies 
reported TIV as less effective and more costly that the 
alternative vaccination options [12, 14, 23]. One study 
in children reported LAIV as a cost-saving option com-
pared to TIV, from the society perspective in Germany 
[12]. Two studies reported QIV as a cost-saving option, 
compared to TIV, for the Chinese and the German so-
ciety, and in elderly and whole population, respectively 
[14, 29]. Nine studies reported QIV as cost-effective 
option (but not cost-saving) compared to TIV, from so-
cietal and healthcare system perspective in the whole 
population, elderly and high-risk patients [9, 11, 12, 14, 
15, 18, 22, 27, 30]. In children, LAIV was cost-effective 
from the payers’ perspective if compared to TIV, and 
also from the societal perspective if compared to IIV 
[12, 25]. All cost-effectiveness ratios, comparing differ-
ent vaccines and vaccination strategies, are reported in 
Table 2. 
DISCUSSION
In the current era of budget constraints, it is nec-
essary to make decisions on how to best allocate the 
limited available resources, and to establish priorities. 
Influenza vaccination is recognized for its potential 
Table 2
Continued
All population Children Adult Elderly Pregnant High-Risk
Canada (3) ICER for QIV: 7,961 $/
QALY-11,211 $/LY
[18]
ICER for 
vaccination vs 
No vaccination 
164.12 $ (per 
case of influenza 
adverted) [28]
ICER for QIV: 62,792-
94,248 $/QALY [27]
China (3) ICER for QIV was 
12,558-22,603 $/
QALY [30]
ICER for IM vaccination: 
14,528 $/ QALY [31]
QIV was cost-saving 
[29]
Turkey (1) ICER for 
projected 
situation: 64-
1,158 TRY/QALY 
from SP and PP 
[32]
Israel (1) Vaccination was 
cost-saving [35]
Thailand (1) ICER for TIV vs 
No vaccination: 
4,445 $/DALY:  
ICER for LAIV vs 
No vaccination: 
1,841-5,748 $/
DALY [33]
Australia (1) ICER for vaccination 
vs No vaccination was 
27.968 A$/QALY (with 
vaccine efficacy of 40 
%) [34]
TIV: Trivalent Inactivated Influenza Vaccine, QIV: Quadrivalent Inactivated Influenza Vaccine, LAIV: Live Attenuated Influenza Vaccine, IIV: Inactivated Vaccine, HD: 
High-dose, IM: Intra-Muscular, LYs: Life Years, QALYs: Quality Adjusted Life Years, DALYs: Disability Adjusted Life Years; SP: Societal Perspective; PP: Payer Perspective.
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benefits in terms of preventing cases of influenza and 
reducing complications, however the implementation 
of vaccination programs may require a noticeable eco-
nomic investment. 
We found that the majority of influenza cost-effec-
tiveness analyses were performed in high-income coun-
tries and reported influenza vaccination as cost-saving 
in children and cost-effective in the elderly, in line with 
Paesah et al. [6]. All analyses found that influenza vac-
cination is always more effective than no vaccination; it 
is cost-saving in children and in high risk patients (from 
the payer perspective) and in pregnant women and 
in the general population (from the societal perspec-
tive) [16, 17, 20, 35]. Vaccinating children is likely to 
be cost-saving in the short and long term time horizon 
because of an indirect effect that protects entire com-
munities, given that the children are considered major 
propagators of influenza [26, 28]. On the other hand, 
vaccinating elderly is also associated with a reduction in 
hospitalizations [15, 36]. Further, we found that mater-
nal vaccination during pregnancy was an economically 
favorable approach to prevent influenza also in young 
infants. In US, vaccination during pregnancy was cost-
effective and cost-beneficial from payer and societal 
perspective, compared to no vaccination [7, 20]. Fur-
thermore, seasonal influenza vaccination in pregnant 
women was cost-effective from the societal perspective 
also in Europe [8]. Among new strategies to improve 
the efficacy of influenza vaccines, many studies com-
pared trivalent vaccines with more recent quadrivalent 
products. Cost-effectiveness of QIV was reported in 
different subgroups and countries [9, 11, 14, 15, 18, 22, 
27, 29, 30], showing that QIV could be a cost-effective 
option compared to TIV in the elderly and at high risk 
individuals [5, 9].
Our review showed different cost-effectiveness esti-
mates of influenza vaccination programs, depending on 
the country where the analysis was carried out. These 
differences could depend on influenza activity, meth-
ods applied, population type and vaccine uptake; but 
also on differences in income and healthcare systems. 
For example, Xu et al. 2016, using a decision-analytic 
model, evaluated the cost-effectiveness of vaccinating 
pregnant women, from a societal perspective, in the 
US [20]. They built three different scenarios (simu-
lating three recent influenza seasons) and concluded 
that, compared to a no vaccination strategy, vaccinat-
ing pregnant women against influenza was cost-saving 
in moderate or severe influenza seasons, but not in 
mild influenza seasons [20]. Thommes et al. assessed 
the cost effectiveness of a nationwide switch from TIV 
to QIV, in Canada and the UK, from payer’s perspec-
tive, developing an age-stratified dynamic transmission 
model [18]. Despite the switch from TIV to QIV be-
ing reported as highly cost-effective in both countries, 
the authors found a significantly greater relative im-
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Stratification studies performed by patients’ group and perspective vs No vaccination (A. Payer and B. Society).
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pact from the switch in Canada compared to the UK. 
The difference is mainly due to lower vaccine uptake 
in UK, as compared to Canada [18]. Joyce You et al. 
evaluated the cost-effectiveness of QIV versus TIV, in 
the Hong Kong population showing significantly differ-
ent results in different age groups and with different 
analyses perspective. QIV was cost-effective in all age 
groups except 15-64 years, from the societal perspec-
tive. From the healthcare provider’s perspective, QIV 
was cost-effective in young children (6 months-9 years) 
and elderly (≥ 80 years), but not cost-effective in other 
age groups (10-79 years) [30]. When vaccines with dif-
ferent method of administration were considered, the 
cost-effectiveness results were highly dependent on 
vaccine effectiveness and population type. Some recent 
studies estimated that the cost-effectiveness results of 
LAIV in children aged 2-8 years were highly sensitive 
to effectiveness variation [25, 26]. At last, concerning 
the methods used, the cost-effectiveness of vaccination 
was assessed using a wide range of models, including 
decision tree models, dynamic models, Markov models, 
etc., and some models did not include impact of herd 
immunity generated by vaccine coverage. Therefore, 
some studies could have underestimated the benefits of 
influenza vaccination programs.
A major limitation of our review is that we carried 
out a mainly descriptive review, with little evaluation 
of the qualities of the included studies. Nevertheless, 
in accordance to the aim of our study, we performed a 
systematic search of the literature, to reflect on current 
available data on cost-effectiveness of influenza vacci-
nation, and to briefly summarize them with a particular 
focus on target groups and sub-populations.
CONCLUSIONS
Most of the studies found that influenza vaccination 
is cost-saving in children and generally cost-effective, 
particularly in the elderly and in pregnant women. Per-
forming appropriate economic evaluations based on 
good clinical and economic data and rigorous meth-
odology is of primary importance in order to make ad-
equate decisions on the allocation of available resources 
for vaccination programs
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